PriceTargets.com logo

OpGen - OPGN Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $3.00
  • Forecasted Upside: 339.88%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$0.68 As of 06/5/2023 01:03 PM ET
▼ -0.0184 (-2.63%)

This chart shows the closing price for OPGN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New OpGen Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for OPGN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for OPGN

Analyst Price Target is $3.00
▲ +339.88% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for OpGen in the last 3 months. The average price target is $3.00, with a high forecast of $3.00 and a low forecast of $3.00. The average price target represents a 339.88% upside from the last price of $0.68.

This chart shows the closing price for OPGN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 2 polled investment analysts is to buy stock in OpGen. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/12/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/12/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/10/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/8/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/7/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/7/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
5/6/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/5/2023

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
7/19/2022Alliance Global PartnersDowngradeNeutralLow
7/11/2022Alliance Global PartnersDowngradeBuy ➝ NeutralN/A
6/10/2022HC WainwrightReiterated RatingBuy$3.00High
5/31/2022Alliance Global PartnersReiterated RatingBuy ➝ Buy$1.25High
5/27/2022HC WainwrightReiterated RatingBuy$3.00High
5/13/2022HC WainwrightLower Target$4.00 ➝ $3.00High
1/12/2022Alliance Global PartnersLower Target$4.35 ➝ $3.00High
12/15/2021HC WainwrightReiterated RatingBuy$4.00High
10/22/2021HC WainwrightReiterated RatingBuyMedium
9/30/2021UBS GroupInitiated CoveragePositiveLow
3/15/2021HC WainwrightReiterated RatingBuy$4.00Low
3/2/2021Alliance Global PartnersBoost TargetBuy$5.65 ➝ $7.00High
11/13/2020Alliance Global PartnersBoost TargetBuy$5.00 ➝ $5.65Low
10/19/2020HC WainwrightReiterated RatingBuyMedium
6/9/2020Alliance Global PartnersReiterated RatingBuy$5.00High
9/9/2019AegisSet TargetBuy$20.00Low
5/19/2019HC WainwrightReiterated RatingBuy$1.50High
3/1/2019Alliance Global PartnersInitiated CoverageBuy$2.30Medium
12/5/2018HC WainwrightSet TargetBuy$6.00Low
11/14/2018HC WainwrightSet TargetBuy$6.00Medium
11/7/2018HC WainwrightSet TargetBuy$6.00Low
11/1/2018HC WainwrightSet TargetBuy$6.00High
8/3/2018HC WainwrightSet TargetBuy$8.00High
(Data available from 6/5/2018 forward)

News Sentiment Rating

0.12 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/7/2022
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/7/2022
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/6/2023
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/5/2023
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/7/2023
  • 2 very positive mentions
  • 8 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
4/6/2023
  • 5 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/6/2023
  • 0 very positive mentions
  • 14 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/5/2023

Current Sentiment

  • 0 very positive mentions
  • 14 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
OpGen logo
OpGen, Inc. is a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease. It engages in the development of molecular information products and services for global healthcare settings. The firm's also offers guidance to clinicians about life threatening infections, improving patient outcomes, and decreasing the spread of infections caused by multidrug-resistant microorganisms. Its products include Unyvero, Acuitas AMR Gene Panel and Acuitas Lighthouse, and the ARES Technology Platform including ARESdb, using NGS technology and AI-powered bioinformatics solutions for antibiotic response prediction. The company was founded on January 22, 2001 and is headquartered in Gaithersburg, MD.
Read More

Today's Range

Now: $0.68
Low: $0.68
High: $0.72

50 Day Range

MA: $0.95
Low: $0.68
High: $1.46

52 Week Range

Now: $0.68
Low: $0.55
High: $13.60

Volume

60,520 shs

Average Volume

395,250 shs

Market Capitalization

$3.76 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of OpGen?

The following sell-side analysts have issued reports on OpGen in the last twelve months: Alliance Global Partners, HC Wainwright, and StockNews.com.
View the latest analyst ratings for OPGN.

What is the current price target for OpGen?

1 Wall Street analysts have set twelve-month price targets for OpGen in the last year. Their average twelve-month price target is $3.00, suggesting a possible upside of 339.9%. HC Wainwright has the highest price target set, predicting OPGN will reach $3.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $3.00 for OpGen in the next year.
View the latest price targets for OPGN.

What is the current consensus analyst rating for OpGen?

OpGen currently has 1 hold rating and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe OPGN will outperform the market and that investors should add to their positions of OpGen.
View the latest ratings for OPGN.

What other companies compete with OpGen?

Other companies that are similar to OpGen include Fresh2 Group, Aclarion, Vyant Bio, Biocept and TransCode Therapeutics. Learn More about companies similar to OpGen.

How do I contact OpGen's investor relations team?

OpGen's physical mailing address is 708 QUINCE ORCHARD ROAD SUITE 205, GAITHERSBURG MD, 20878. The medical research company's listed phone number is (240) 813-1260 and its investor relations email address is [email protected]. The official website for OpGen is www.opgen.com. Learn More about contacing OpGen investor relations.